Clinical Trials

Clinical Trial Detail

Return to search results.

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Complete title: A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients with Bladder Cancer

Research Study Number       8027
    
Principal Investigator       Robert Montgomery, MD
    
Phase       I/II

Look up trial at NIH

Research Study Description

This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer. Biological therapies, such as sirolimus, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sirolimus together with cisplatin and gemcitabine hydrochloride may be an effective treatment for bladder cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information

- Histologically or cytologically confirmed carcinoma of the bladder of all histologies except neuroendocrine differentiation or squamous cell histology

- Eastern Cooperative Oncology Group (ECOG) performance status of =< 1

- Eligibility for phase 1 and phase 2 components:

-- * Phase 1 - clinical T3 or T4 or N1 or M1 cancer which is untreated or previously treated with platinum based therapy with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicated

-- * Phase 2 - clinical T2-4 N0 or N1 untreated with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicated

- Life expectancy >= 12 weeks

- No prior malignancy is allowed except:

-- * Adequately treated basal cell or squamous cell skin cancer or

-- * In situ carcinoma of any site or

-- * Other adequately treated malignancy for which the patient is currently disease free for at least one year

- Absolute neutrophil count >= 1.5 x 10^9 cells/L

- Hemoglobin (Hgb) >= 9.0 g/dL

- Platelets >= 100,000 x 10^9/L

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)

- Bilirubin and total bilirubin levels =< 1.5 x ULN

- Serum creatinine < 1.5 mg/dL OR creatinine clearance >= 50 mL/min

- All pre-study labs required for determination of eligibility are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday)

- X-rays and/or scans to assess all disease sites are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday)

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients currently receiving active therapy for other neoplastic disorders

- Known parenchymal brain metastasis

- Active or symptomatic viral hepatitis or chronic liver disease

- Estimated creatinine clearance less than 50 ml/minute

- Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < 45 % at baseline, if done

- Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy

- Administration of an investigational therapeutic within 30 days of cycle 1, day 1

- Patients with dementia/psychiatric illness/social situations that would limit compliance with study requirements or would prohibit the understanding and/or giving of informed consent

- Patients with medical conditions, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained will not be eligible

- Any condition which, in the opinion of the investigator, would preclude participation in this trial

Other exclusion criteria may apply.



Research Study Number       8027
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Bladder Cancer; Genitourinary Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials